MAPT and Alzheimer disease: Besides, Aβ's polymorphism [37, 38] may yield new conformers that cannot be blocked by aducanumab [37–39]; hence, they would be able to induce a damaging enzymatic tau phosphorylation (Figure 2(b)), a situation that may explain the lack of long-term AD protection in the presence of aducanumab, an observation that may apply to other mAbs.